[Autologous stem cell harvesting after high dosage chemo- and/or growth factor therapy].
5 patients with metastatic tumors and 4 patients with hematological malignancies were treated either with G- or GM-CSF alone (5 micrograms/kg s.c.) or in combination with cyclophosphamide (7 g/m2) or epirubicin (120 mg/m2) to reduce either tumor mass or to maintain remission and to prime for peripheral stem cell collection.
Kasparu
H
H
I. Internen Abteilung, Krankenhauses der Elisabethinen, Linz.
Krieger
O
O
Bettelheim
P
P
Kolb
A
A
Lutz
D
D
D000328:Adult; D001772:Blood Cell Count; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D016238:Cytapheresis; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D015996:Survival Rate; D014182:Transplantation, Autologous
D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide